NCT00697840View on ClinicalTrials.gov

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 30, 1995

Primary Completion Date

January 31, 1996

Study Completion Date

January 31, 1996

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Engerix™-B

Intramuscular injection, 2 doses

BIOLOGICAL

HBV-MPL 208129

Intramuscular injection, 2 doses

BIOLOGICAL

Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation

Intramuscular injection, 2 doses; experimental formulation

Trial Locations (1)

Unknown

GSK Clinical Trials Call Center, Vienna

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY